Entrada Therapeutics (TRDA) Depreciation & Amortization (CF) (2020 - 2026)

Entrada Therapeutics' Depreciation & Amortization (CF) history runs 7 years deep, the most recent figure standing at $800000.0 for Q1 2026.

• In Q1 2026, Depreciation & Amortization (CF) fell 11.11% year-over-year to $800000.0; the TTM figure through Mar 2026 stood at $4.0 million (up 8.52% YoY), while the FY2025 annual figure was $4.1 million, up 8.56% from the prior year.
• Depreciation & Amortization (CF) was $800000.0 for Q1 2026 at Entrada Therapeutics, down from $886000.0 in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $1.2 million in Q3 2025 to a low of $390000.0 in Q1 2022.
• Historically, Depreciation & Amortization (CF) has averaged $777411.8 across 5 years, with a median of $800000.0 in 2023.
• The sharpest annual moves came in 2022 and 2026: Depreciation & Amortization (CF) soared 95.98% in 2022, then slipped 11.11% in 2026.
• A 5-year view of Depreciation & Amortization (CF) shows it stood at $531000.0 in 2022, then soared by 30.89% to $695000.0 in 2023, then surged by 40.0% to $973000.0 in 2024, then decreased by 8.94% to $886000.0 in 2025, then dropped by 9.71% to $800000.0 in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $800000.0 (Q1 2026), $886000.0 (Q4 2025), and $1.2 million (Q3 2025), per Business Quant data.